Newsroom

NEW YORK--(BUSINESS WIRE)--OneSpaWorld Holdings Limited, (NASDAQ: OSW), the pre-eminent global provider of health and wellness products and services on board cruise ships and in destination resorts around the world, announced today that it will release its First Quarter Fiscal 2026 earnings on Wednesday, April 29th before market open. The Company will conduct a conference call the same day at 10:00 am ET to discuss its quarterly results. What: OneSpaWorld First Quarter Fiscal 2026 financial res...

MIAMI LAKES, Fla.--(BUSINESS WIRE)--BankUnited, Inc. Reports 1Q 2026 Results...

DALLAS--(BUSINESS WIRE)--Jacobs, GHD and WSP appointed in a joint venture to design five new underground stations for Sydney Metro West – Stations Package West, Australia....

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Nasdaq Cybersecurity UCITS ETF 21.04.2026 NQCYBREN IE00BF16M727 29,661,611.00 USD 1,235,995,329.46 41.670  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Moderate Buffer UCITS ETF - May 21.04.2026 GMAY.LN IE000P0FL8E3 900,002.00 USD 35,358,198.47 39.287  ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) gab heute bekannt, dass die vollständigen Ergebnisse der zulassungsrelevanten Phase-3-Studie zur Bewertung von Tafasitamab (Monjuvi®/Minjuvi®) bei der Erstlinienbehandlung des diffusen großzelligen B-Zell-Lymphoms (DLBCL) im Rahmen einer mündlichen Präsentation auf der Jahrestagung 2026 der American Society of Clinical Oncology (ASCO) vorgestellt werden, die vom 29. Mai – 2. Juni 2026 in Chicago stattfindet. „Die positiven Ergebnisse der P...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust NYSE Arca Biotechnology UCITS ETF 21.04.2026 FBTU.LN IE00BL0L0H60 475,002.00 USD 12,077,488.64 25.426  ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) kondigde vandaag aan dat de volledige resultaten uit de cruciale Fase 3-studie, ter beoordeling van tafasitamab (Monjuvi®/Minjuvi®) in eerstelijns DLBCL (diffuse large b-cell lymphoma = diffuus grootcellig B-cellymfoom) tijdens een mondelinge presentatie zullen worden voorgesteld op de 2026 ASCO (American Society of Clinical Oncology) Annual Meeting, die doorgaat van 29 mei tot 2 juni 2026 in Chicago. “De positieve Fase 3 frontMIND-resulta...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) anunció hoy que los resultados completos del estudio pivotal de fase 3 que evalúa el tafasitamab (Monjuvi®/Minjuvi®) como tratamiento de primera línea en casos de linfoma difuso de células B grandes (DLBCL) se presentarán en el marco de una sesión oral en el Congreso Anual 2026 de la American Society of Clinical Oncology (ASCO), que se celebrará del 29 de mayo al 2 de junio de 2026 en Chicago. «Los resultados positivos del estudio frontMI...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq : INCY) a annoncé aujourd’hui que les résultats complets de l’étude pivot de phase III évaluant le tafasitamab (Monjuvi®/Minjuvi®) en traitement de première intention du lymphome diffus à grandes cellules B (LDGCB) seront présentés lors d’une communication orale au congrès annuel 2026 de l’American Society of Clinical Oncology (ASCO), qui se tiendra à Chicago du 29 mai au 2 juin 2026. « Les résultats positifs de l’étude de phase III frontMIND év...